Lobbying for continued funding from the government for rare disease research and development, including through the Rare Pediatric Disease Designation and Priority Review Voucher Programs; advocating for greater awareness about the rare disease community for doctors via the Give Kids a Chance Act.
2025 · 4th Quarter (Oct 1 - Dec 31)
QUOIN PHARMACEUTICALS, INC.
Filed by FORWARD GLOBAL.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- FORWARD GLOBAL
- Filing UUID
- 8ef77455-e42f-49c9-acf2-820eac2aed0a
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Lobbying for continued funding from the government for rare disease research and development, including through the Rare Pediatric Disease Designation and Priority Review Voucher Programs; advocating for greater awareness about the rare disease community for doctors via the Give Kids a Chance Act.
Lobbying for continued funding from the government for rare disease research and development, including through the Rare Pediatric Disease Designation and Priority Review Voucher Programs; advocating for greater awareness about the rare disease community for doctors via the Give Kids a Chance Act.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.